PÕ¾ÊÓƵ

Advani R. Optimal therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2011. 2011; 310−316.

Aisenberg AC. Problems in Hodgkin's disease management. Blood. 1999;93:761-779.

PÕ¾ÊÓƵ. Cancer Facts & Figures 2016. Atlanta, Ga: PÕ¾ÊÓƵ; 2016.

PÕ¾ÊÓƵ. Cancer Facts & Figures 2017. Atlanta, Ga: PÕ¾ÊÓƵ; 2017.

Armitage JO. Early-stage Hodgkin’s lymphoma. New Engl J Med. 2010;363:653−662.

Bartlett NL, Foyil KV. Chapter 105: Hodgkin lymphoma. In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa. Elsevier: 2014.

Children’s Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers. Accessed at www.survivorshipguidelines.org/ on 11/20/14.

Clarke C, O’Malley C, Glaser S. Hodgkin lymphoma. In: Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J, eds. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD, 2007.

Dores GM, Coté TR, Travis LB. New Malignancies Following Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and Myeloma. In: Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr. (eds). New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. National Cancer Institute. NIH Publ. No. 05-5302. Bethesda, MD, 2006. Accessed on 4/18/2014 at http://seer.cancer.gov/archive/publications/mpmono/MPMonograph_complete.pdf.

Dores GM, Melayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin’s disease: A population-based evaluation over 25 years. J Clin Oncol. 2002;20:3484–3494.

Engert A, Eichenauer DA, Harris NL, Diehl V. Chapter 126: Hodgkin lymphoma. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011.

Hemminki K, Lenner P, Sundquist J, Bermejo JL. Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis. J Clin Oncol. 2008;26:1850-1857.

Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.

Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera EV, Gapstur S, Patel AV, Andrews K, Gansler T; PÕ¾ÊÓƵ 2010 Nutrition and Physical Activity Guidelines Advisory Committee. PÕ¾ÊÓƵ Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2012 Jan-Feb;62(1):30-67.

Mudie NY, Swerdlow AJ, Higgins CD, et al. Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. J Clin Oncol. 2006;24:1568-1574.

National Cancer Institute. Physician Data Query (PDQ). Adult Hodgkin Lymphoma Treatment. 2014. Accessed at www.cancer.gov/cancertopics/pdq/treatment/adulthodgkins/HealthProfessional on June 20, 2014.

National Cancer Institute. Physician Data Query (PDQ). Childhood Hodgkin Lymphoma Treatment. 2014. Accessed at www.cancer.gov/cancertopics/pdq/treatment/childhodgkins/HealthProfessional on June 20, 2014.

National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Hodgkin Lymphoma. Version 2.2014. Accessed at www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf on June 20, 2014.

Ramchandren R. Advances in the treatment of relapsed or refractory Hodgkin’s lymphoma. Oncologist. 2012;17:367−376.

Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52:611−622.

Townsend W, Linch D. Hodgkin's lymphoma in adults. Lancet. 2012; 380:836−847.

Yahalom J, Straus D. Hodgkin lymphoma. In: Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ, eds. Cancer Management: A Multidisciplinary Approach. 13th ed. Lawrence, KS: UBM Medica; 2010:715−738.

Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812−1821.

Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: Results of a phase II study. J Clin Oncol. 2012;30:2197−2203.